MedTrace Logo

Study of the Ability of a Flu Vaccine to Prevent Flu Infection

NCT00349037 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2007-01-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate how effective the vaccine is at preventing subjects developing flu symptoms after they are directly exposed to flu virus. The study will also evaluate how well the vaccine is tolerated at sites where administrations are given, any effects it may have on subjects' wellbeing and whether it can produce antibody responses in the body

Conditions

Interventions

BIOLOGICAL

Trivalent DNA vaccine with and without pPJV2012 administered by PMED

Sponsors & Collaborators

  • PowderMed

    lead INDUSTRY

Principal Investigators

  • Tim Mant, BSc, FRCP, FFPM · GDRU

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Completion
2007-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00349037 on ClinicalTrials.gov